top of page
TD Securities Reiterates Buy Rating for Cronos Group Amid Strong Q1

TD Securities Reiterates Buy Rating for Cronos Group Amid Strong Q1

TD Securities Reiterates Buy Rating for Cronos Group (NASDAQ: CRON) Amid Strong Q1 Performance

  • Cronos Group (NASDAQ: CRON) received a reiterated Buy rating from TD Securities following a record-breaking Q1 2026, showcasing strong revenue growth.
  • The cannabis company achieved its highest-ever net revenue of CAD 45.2 million and a gross profit of CAD 19.2 million, driven by market share leadership in Canadian vapes and international expansion.
  • Despite a slight dip in earnings per share to $0.01, Cronos Group surpassed revenue estimates by 6.94% and maintained a robust financial position with $822 million in cash.

On May 12, 2026, investment bank TD Securities reiterated its Buy rating for Cronos Group. At the time of the rating, the stock price was $2.76. Cronos Group is a global cannabis company focused on producing and selling cannabis products for both medical and adult-use markets.

This rating follows a record-breaking first quarter for Cronos Group in 2026. The company achieved its highest-ever net revenue, totaling CAD 45.2 million, representing a 40% increase from the same period last year. Gross profit, which reflects revenue minus the cost of goods sold, was CAD 19.2 million.

The company’s growth was driven by strong performance in key markets. In Canada, its Spinach brand secured the number one market share position in vapes. Higher sales of cannabis flower and extracts in Canada and Israel also contributed significantly to the revenue increase.

Internationally, Cronos Group continued to expand its presence. Its PEACE NATURALS® brand remained the top cannabis brand in Israel, achieving record net revenue for the ninth consecutive quarter. The company also maintained a strong financial position, with $822 million in cash and cash equivalents on its balance sheet.

For the quarter, Cronos Group reported earnings of $0.01 per share, in line with the Zacks Consensus Estimate. While this was down from $0.02 per share a year earlier, total revenue of $45.21 million exceeded analyst estimates by 6.94%. This marked the third time in the last four quarters that the company beat revenue expectations.

Want to know when to buy this stock? Download the Stocks 2 Buy app or try the Web version

Group 82_edited.png

Forecast your chosen stock price with the Stock Sentiment Map

Comments

Share Your ThoughtsBe the first to write a comment.
Copy of Logo circular simple negro.png
bottom of page